<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Hypotheses</journal-id><journal-id journal-id-type="iso-abbrev">Med. Hypotheses</journal-id><journal-title-group><journal-title>Medical Hypotheses</journal-title></journal-title-group><issn pub-type="ppub">0306-9877</issn><issn pub-type="epub">1532-2777</issn><publisher><publisher-name>Eden Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7371587</article-id><article-id pub-id-type="pii">S0306-9877(20)32103-4</article-id><article-id pub-id-type="doi">10.1016/j.mehy.2020.110125</article-id><article-id pub-id-type="publisher-id">110125</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Possible mechanisms responsible for acute coronary events in COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Sheth</surname><given-names>Aakash R.</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Grewal</surname><given-names>Udhayvir S.</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au015"><name><surname>Patel</surname><given-names>Harsh P.</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au020"><name><surname>Thakkar</surname><given-names>Samarthkumar</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au025"><name><surname>Garikipati</surname><given-names>Subhash</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au030"><name><surname>Gaddam</surname><given-names>Jashwanth</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au035"><name><surname>Bawa</surname><given-names>Danish</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><aff id="af005"><label>a</label>The Department of Internal Medicine, LSU Health Sciences Center, Shreveport, LA, United States</aff><aff id="af010"><label>b</label>The Department of Internal Medicine, Louis A Weiss Memorial Hospital, Chicago, IL, United States</aff><aff id="af015"><label>c</label>The Department of Internal Medicine, Rochester General Hospital, Rochester, NY, United States</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author.</corresp></author-notes><pub-date pub-type="pmc-release"><day>21</day><month>7</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>10</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>21</day><month>7</month><year>2020</year></pub-date><volume>143</volume><fpage>110125</fpage><lpage>110125</lpage><history><date date-type="received"><day>6</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>11</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>17</day><month>7</month><year>2020</year></date></history><permissions><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab005"><p>The novel coronavirus (SARS-CoV-2) is primarily a respiratory pathogen and its clinical manifestations are dominated by respiratory symptoms, the most severe of which is acute respiratory distress syndrome (ARDS). However, COVID-19 is increasingly recognized to cause an overwhelming inflammatory response and cytokine storm leading to end organ damage. End organ damage to heart is one of the most severe complications of COVID-19 that increases the risk of death. We proposed a two-fold mechanism responsible for causing acute coronary events in patients with COVID-19 infection: Cytokine storm leading to rapid onset formation of new coronary plaques along with destabilization of pre-existing plaques and direct myocardial injury secondary to acute systemic viral infection. A well-coordinated immune response is the first line innate immunity against a viral infection. However, an uncoordinated response and hypersecretion of cytokines and chemokines lead to immune related damage to the human body. Human Coronavirus (HCoV) infection causes infiltration of inflammatory cells that cause excessive production of cytokines, proteases, coagulation factors, oxygen radicals and vasoactive molecules causing endothelial damage, disruption of fibrous cap and initiation of formation of thrombus. Systemic viral infections also cause vasoconstriction leading to narrowing of vascular lumen and stimulation of platelet activation via shear stress. The resultant cytokine storm causes secretion of hypercoagulable tissue factor without consequential increase in counter-regulatory pathways such as AT-III, activated protein C and plasminogen activator type 1. Lastly, influx of CD4+ T-cells in cardiac vasculature results in an increased production of cytokines that stimulate smooth muscle cells to migrate into the intima and generate collagen and other fibrous products leading to advancement of fatty streaks to advanced atherosclerotic lesions. Direct myocardial damage and cytokine storm leading to destabilization of pre-existing plaques and accelerated formation of new plaques are the two instigating mechanisms for acute coronary syndromes in COVID-19.</p></abstract></article-meta></front><body><sec id="s0005"><title>Introduction</title><p id="p0005">In December 2019, an outbreak of the novel coronavirus disease occurred in Wuhan, China that has subsequently been termed the Coronavirus Disease- 2019 (COVID-19). Like other coronaviruses, the novel coronavirus (SARS-CoV-2) is primarily a respiratory pathogen and its clinical manifestations are dominated by respiratory symptoms, the most severe of which is acute respiratory distress syndrome (ARDS). However, COVID-19 has been increasingly recognized to cause an overwhelming inflammatory response and cytokine storm subsequently resulting in multi-systemic end organ damage <xref rid="b0005" ref-type="bibr">[1]</xref>. End organ damage to the heart has emerged as one of the most severe complications of COVID-19 that significantly increases the overall mortality in these patients <xref rid="b0010" ref-type="bibr">[2]</xref>. Patients with pre-existing cardiac conditions have been observed to have a heightened cytokine storm leading to more significant cardiac injury and worse overall outcomes <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>. Among the various cardiac manifestations of COVID-19 are acute myocardial injury (AMI), left ventricular systolic dysfunction, heart failure, arrhythmias and acute coronary events <xref rid="b0025" ref-type="bibr">[5]</xref>. While there is a lack of medical literature regarding the association of acute coronary events in COVID-19 patients, data can be extrapolated from previous clinical and epidemiological studies in Influenza and acute inflammatory conditions <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0040" ref-type="bibr">[8]</xref>, <xref rid="b0045" ref-type="bibr">[9]</xref> that are also known to cause systemic inflammatory stress. Existing studies have proposed multiple pathophysiologic mechanisms for AMI in the setting of these viral infections. These include, inflammatory and increased shear stress causing plaque rupture leading to acute coronary event, aggravation of pre-existing coronary artery disease causing more severe cardiac injury and other direct and indirect causes of myocardial injuries (<xref rid="f0005" ref-type="fig">Fig. 1</xref>
).<fig id="f0005"><label>Fig. 1</label><caption><p>Possible mechanisms for causation of Acute Coronary Events in COVID-19. SARS-CoV-2 can cause acute coronary events either directly through direct myocardial injury or indirectly through cytokines and chemokines.</p></caption><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0010">In this piece, we aim to further hypothesize and discuss possible pathophysiologic mechanisms for acute coronary events in COVID-19 infection.</p><sec id="s0010"><title>Cytokine storm in systemic viral infections</title><p id="p0015">It is well known that cytokines play an important role in the pathology of a systemic viral illness. A well-coordinated immune response is a part of the first line innate immunity against most viral infections. However, an uncoordinated response results in the hyper-secretion of cytokines and chemokines which further lead to immune related end-organ damage <xref rid="b0060" ref-type="bibr">[12]</xref>. HCoV (human coronavirus) infection triggers the release of cytokines (IL-6, IL-1B and TNF) and chemokines (CCL-2, CCL-3, and CCL-5) from respiratory epithelial cells, dendritic cells (DCs) and macrophages <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>. Rapidly increasing cytokines and chemokines attract inflammatory cells such as neutrophils and monocytes, causing excessive infiltration of inflammatory cells in lungs and other organs. Through a positive feedback mechanism, the rapid infiltration of monocytes into organs triggers the elevation of proinflammatory cytokines (TNF, IL-6, IL1B and iNOS) which subsequently intensifies the systemic inflammatory response. Additionally, these mononuclear macrophage-derived proinflammatory cytokines induce apoptosis of T cells, which further decreases the viral clearance and results in propagation of the disease <xref rid="b0050" ref-type="bibr">[10]</xref>. Another consequence of rapid viral replication, inhibition of viral clearance and the over-abundance of inflammatory cytokines is the induction of apoptosis of end organ epithelial and endothelial cells through FAS-FAS ligand (FASL) or TRAIL-death receptor 5 (DR5) <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>. These mechanisms lead to severe end organ damage including, but not limited to, Acute Respiratory Distress Syndrome (ARDS).</p><p id="p0020">Similar to patients affected by other HCoV (SARS, and MERS), patients with COVID-19 have elevated levels of IL-2R and IL-6, which positively correlate with the overall severity of the disease<sup>2</sup>. In COVID-19, the severity of cytokine storm has been recognized an important factor in predicting the clinical course of extrapulmonary organ failure and mortality <xref rid="b0090" ref-type="bibr">[18]</xref>.</p></sec></sec><sec id="s0015"><label>Hypothesis</label><p id="p0025">Respiratory viral infections have been known to be associated with an increased risk of cardiovascular morbidity and mortality <xref rid="b0035" ref-type="bibr">[7]</xref>. Systemic inflammation caused by the viral infections plays a key role in the pathogenesis of acute coronary syndromes in these patients <xref rid="b0095" ref-type="bibr">[19]</xref>.</p><p id="p0030">We hypothesize a bi-faced mechanism for the occurrence of acute coronary events in an acute systemic viral infection:<list list-type="simple" id="l0005"><list-item id="o0005"><label>1.</label><p id="p0035">Rapid new onset formation of coronary plaques along with acute plaque change (APC) in pre-existing plaques,</p></list-item><list-item id="o0010"><label>2.</label><p id="p0040">Direct myocardial injury secondary to acute systemic viral infection.</p></list-item></list>
</p><p id="p0045">Acute myocardial infarction in influenza and human coronavirus like infections is well studied <xref rid="b0035" ref-type="bibr">[7]</xref>. Given the scarcity of information about COVID-19 and its stark similarity with respiratory viral syndromes, it is prudent to extrapolate information to better understand the pathophysiology behind cardiovascular complications of COVID-19.</p></sec><sec id="s0020"><title>Evaluation of hypothesis</title><sec id="s0025"><title>Destabilization of preexisting plaques in acute systemic viral infections</title><p id="p0050">Most acute coronary syndromes occur due to thrombotic complications at the site of atherosclerotic plaque formation. Disruption of the plaque surface exposes underlying tissue factors, collagen and phospholipids which further causes platelet adhesion and formation of an acute or subacute thrombus. Systemic inflammation after acute viral infections plays a central role in triggering plaque disruption and causation of acute coronary syndromes. When compared to patients with stable coronary artery disease, those with acute coronary syndrome have higher inflammatory markers such as C-reactive protein, procalcitonin, WBC and neutrophil myeloperoxidase across the entire coronary arterial network, in addition to the culprit lesion <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>. As mentioned above, respiratory viruses lead to an increase in infiltration of inflammatory cells (macrophages, neutrophils and T cells) that ultimately produce cytokines, proteases, coagulation factors, oxygen radicals and vasoactive molecules that cause endothelial damage, disrupt fibrous cap and initiate the formation of thrombi <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>.</p></sec><sec id="s0030"><title>Mechanisms causing direct myocardial injury</title><p id="p0055">A pivotal step in the evolution of acute coronary syndrome is the activation of platelets and formation of platelet thrombi. Platelets can be directly activated by pathogens which can in-turn augment the inflammatory process <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>. Acute infections such as influenza also cause coronary vasoconstriction and stimulate platelet activation via shear stress <xref rid="b0135" ref-type="bibr">[27]</xref>. Cytokine storm induced by respiratory viral infections also leads to increased secretion of tissue factor without consequential increase in counter-regulatory pathways such as anti-thrombin III activity, activated protein C and plasminogen activator inhibitor type 1 <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0160" ref-type="bibr">[32]</xref>. This leads to the formation of new onset thrombi that can propagate in size causing myocardial ischemia. Furthermore, severe hypoxemia induced by respiratory viral infections, increased cardiac metabolic demands induced by the subsequent cytokine storm and the eventual decrease in mean arterial pressure owing to sepsis causes further development of myocardial ischemia <xref rid="b0165" ref-type="bibr">[33]</xref>. There is some evidence suggesting presence of heightened plasma viscosity during fever <xref rid="b0170" ref-type="bibr">[34]</xref>, which further increases the chances of myocardial ischemia.</p></sec><sec id="s0035"><title>Accelerated formation of plaques in acute systemic viral infections</title><p id="p0060">Atherosclerosis is an inflammatory condition that begins with endothelial injury. A variety of stimuli are known to cause endothelial injury and help accelerate plaque formation. The inflammatory cells including mononuclear monocytes that arise from systemic viral infections induced chemokines and cytokines play a pivotal role in formation of lipid-laden foam cells. These lipid laden foam cells are hallmarks of atheroma formation. Furthermore, influx of CD4&#x000a0;+&#x000a0;T-cells results in an increased production of cytokines that stimulate smooth muscle cells to migrate to the intima and generate collagen and other fibrous products <xref rid="b0175" ref-type="bibr">[35]</xref>. There is a complex interplay in downstream biochemical processes between various inflammatory cytokines and tissue cells leading to the evolution of fatty streak to advanced atherosclerotic lesions. These lesions, formed during an incident event of COVID-19 can be further propagated during subsequent systemic viral illnesses leading to acute coronary syndrome and contributing to increased cardiovascular disease burden.</p></sec></sec><sec id="s0040"><title>Conclusion</title><p id="p0065">Improved understanding of underlying mechanisms by which COVID-19 causes myocardial injury will help thousands of individuals currently infected by the SARS-CoV2 to take preventive measures and follow up more intensively to achieve early detection, prevention and treatment of subsequent atherosclerotic disease and new onset myocardial injury. While it is known that repeated influenza infections cause proportionally increased risk of MI, it is yet to be determined if repeated infection with SARS-CoV2 is associated with increased risk of MI. However, based on the knowledge of common mechanisms by which systemic viral infections cause multi-organ damage, it is rational to assume that re-infection with SARS-CoV2 and subsequent infection with other viruses will lead to super-added myocardial injury. Therefore, further research is needed to study in detail, the pathophysiologic mechanisms underlying this association and identify high risk groups that can possibly benefit from intensive cardiovascular screening and follow-up.</p></sec><sec id="s0045"><title>Funding</title><p id="p0070">None.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0080">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.J.</given-names></name><name><surname>Ni</surname><given-names>Z.Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N Engl J Med</source><volume>382</volume><issue>18</issue><year>2020</year><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30]</article-title><source>Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>McGoogan</surname><given-names>J.M.</given-names></name></person-group><article-title>Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention</article-title><source>JAMA</source><volume>323</volume><issue>13</issue><year>2020</year><fpage>1239</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id><pub-id pub-id-type="pmid">32091533</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name></person-group><article-title>Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China</article-title><source>Clin Res Cardiol</source><volume>109</volume><issue>5</issue><year>2020</year><fpage>531</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1007/s00392-020-01626-9</pub-id><pub-id pub-id-type="pmid">32161990</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>M.</given-names></name></person-group><article-title>Cardiovascular disease and COVID-19</article-title><source>Diabetes Metab Syndr</source><volume>14</volume><issue>3</issue><year>2020</year><fpage>247</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/j.dsx.2020.03.013</pub-id><pub-id pub-id-type="pmid">32247212</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Madjid</surname><given-names>M.</given-names></name><name><surname>Miller</surname><given-names>C.C.</given-names></name><name><surname>Zarubaev</surname><given-names>V.V.</given-names></name></person-group><article-title>Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects</article-title><source>Eur Heart J</source><volume>28</volume><issue>10</issue><year>2007</year><fpage>1205</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehm035</pub-id><pub-id pub-id-type="pmid">17440221</pub-id></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>J.L.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Matte</surname><given-names>T.D.</given-names></name><name><surname>Shaman</surname><given-names>J.</given-names></name><name><surname>Kinney</surname><given-names>P.L.</given-names></name></person-group><article-title>Seasonal Influenza Infections and Cardiovascular Disease Mortality</article-title><source>JAMA Cardiol</source><volume>1</volume><issue>3</issue><year>2016</year><fpage>274</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2016.0433</pub-id><pub-id pub-id-type="pmid">27438105</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>J.C.</given-names></name><name><surname>Schwartz</surname><given-names>K.L.</given-names></name><name><surname>Campitelli</surname><given-names>M.A.</given-names></name></person-group><article-title>Acute myocardial infarction after laboratory-confirmed influenza infection</article-title><source>N Engl J Med</source><volume>378</volume><issue>4</issue><year>2018</year><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1702090</pub-id><pub-id pub-id-type="pmid">29365305</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Smeeth</surname><given-names>L.</given-names></name><name><surname>Thomas</surname><given-names>S.L.</given-names></name><name><surname>Hall</surname><given-names>A.J.</given-names></name><name><surname>Hubbard</surname><given-names>R.</given-names></name><name><surname>Farrington</surname><given-names>P.</given-names></name><name><surname>Vallance</surname><given-names>P.</given-names></name></person-group><article-title>Risk of myocardial infarction and stroke after acute infection or vaccination</article-title><source>N Engl J Med</source><volume>351</volume><issue>25</issue><year>2004</year><fpage>2611</fpage><lpage>2618</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa041747</pub-id><pub-id pub-id-type="pmid">15602021</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Fehr</surname><given-names>A.R.</given-names></name><name><surname>Vijay</surname><given-names>R.</given-names></name></person-group><article-title>Dysregulated Type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice</article-title><source>Cell Host Microbe</source><volume>19</volume><issue>2</issue><year>2016</year><fpage>181</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.01.007</pub-id><pub-id pub-id-type="pmid">26867177</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>S.</given-names></name><name><surname>Maini</surname><given-names>M.K.</given-names></name><name><surname>Wack</surname><given-names>A.</given-names></name></person-group><article-title>Disease-promoting effects of type I interferons in viral, bacterial, and coinfections</article-title><source>J Interferon Cytokine Res</source><volume>35</volume><issue>4</issue><year>2015</year><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1089/jir.2014.0227</pub-id><pub-id pub-id-type="pmid">25714109</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>A.C.</given-names></name><name><surname>Goldstein</surname><given-names>D.R.</given-names></name><name><surname>Montgomery</surname><given-names>R.R.</given-names></name></person-group><article-title>Age-dependent dysregulation of innate immunity</article-title><source>Nat Rev Immunol</source><volume>13</volume><issue>12</issue><year>2013</year><fpage>875</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1038/nri3547</pub-id><pub-id pub-id-type="pmid">24157572</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Law</surname><given-names>H.K.</given-names></name><name><surname>Cheung</surname><given-names>C.Y.</given-names></name><name><surname>Ng</surname><given-names>H.Y.</given-names></name></person-group><article-title>Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells</article-title><source>Blood</source><volume>106</volume><issue>7</issue><year>2005</year><fpage>2366</fpage><lpage>2374</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-10-4166</pub-id><pub-id pub-id-type="pmid">15860669</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>S.K.P.</given-names></name><name><surname>Lau</surname><given-names>C.C.Y.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name></person-group><article-title>Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment</article-title><source>J Gen Virol</source><volume>94</volume><issue>Pt 12</issue><year>2013</year><fpage>2679</fpage><lpage>2690</lpage><pub-id pub-id-type="doi">10.1099/vir.0.055533-0</pub-id><pub-id pub-id-type="pmid">24077366</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Herold</surname><given-names>S.</given-names></name><name><surname>Steinmueller</surname><given-names>M.</given-names></name><name><surname>von Wulffen</surname><given-names>W.</given-names></name></person-group><article-title>Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand</article-title><source>J Exp Med</source><volume>205</volume><issue>13</issue><year>2008</year><fpage>3065</fpage><lpage>3077</lpage><pub-id pub-id-type="doi">10.1084/jem.20080201</pub-id><pub-id pub-id-type="pmid">19064696</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>H&#x000f6;gner</surname><given-names>K.</given-names></name><name><surname>Wolff</surname><given-names>T.</given-names></name><name><surname>Pleschka</surname><given-names>S.</given-names></name></person-group><article-title>Macrophage-expressed IFN-&#x003b2; contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia [published correction appears in PLoS Pathog. 2016 Jun;12(6):e1005716]</article-title><source>PLoS Pathog</source><volume>9</volume><issue>2</issue><year>2013</year><comment>e1003188</comment></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Rodrigue-Gervais</surname><given-names>I.G.</given-names></name><name><surname>Labb&#x000e9;</surname><given-names>K.</given-names></name><name><surname>Dagenais</surname><given-names>M.</given-names></name></person-group><article-title>Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival</article-title><source>Cell Host Microbe</source><volume>15</volume><issue>1</issue><year>2014</year><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2013.12.003</pub-id><pub-id pub-id-type="pmid">24439895</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name></person-group><article-title>The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome</article-title><source>Am J Emerg Med</source><volume>26</volume><issue>6</issue><year>2008</year><fpage>711</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2007.10.031</pub-id><pub-id pub-id-type="pmid">18606328</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Biasucci</surname><given-names>L.M.</given-names></name><name><surname>Leo</surname><given-names>M.</given-names></name><name><surname>De Maria</surname><given-names>G.L.</given-names></name></person-group><article-title>Local and systemic mechanisms of plaque rupture</article-title><source>Angiology</source><volume>59</volume><issue>2 Suppl</issue><year>2008</year><fpage>73S</fpage><lpage>76S</lpage><pub-id pub-id-type="doi">10.1177/0003319708319747</pub-id><pub-id pub-id-type="pmid">18544583</pub-id></element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Mauriello</surname><given-names>A.</given-names></name><name><surname>Sangiorgi</surname><given-names>G.</given-names></name><name><surname>Fratoni</surname><given-names>S.</given-names></name></person-group><article-title>Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction</article-title><source>J Am Coll Cardiol</source><volume>45</volume><year>2005</year><fpage>1585</fpage><lpage>1593</lpage><pub-id pub-id-type="pmid">15893171</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Buffon</surname><given-names>A.</given-names></name><name><surname>Biasucci</surname><given-names>L.M.</given-names></name><name><surname>Liuzzo</surname><given-names>G.</given-names></name><name><surname>D'Onofrio</surname><given-names>G.</given-names></name><name><surname>Crea</surname><given-names>F.</given-names></name><name><surname>Maseri</surname><given-names>A.</given-names></name></person-group><article-title>Widespread coronary inflammation in unstable angina</article-title><source>N Engl J Med</source><volume>347</volume><year>2002</year><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">12097534</pub-id></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>A.</given-names></name><name><surname>Shimada</surname><given-names>K.</given-names></name><name><surname>Sano</surname><given-names>T.</given-names></name></person-group><article-title>Multiple plaque rupture and C-reactive protein in acute myocardial infarction</article-title><source>J Am Coll Cardiol</source><volume>45</volume><year>2005</year><fpage>1594</fpage><lpage>1599</lpage><pub-id pub-id-type="pmid">15893172</pub-id></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Corrales-Medina</surname><given-names>V.F.</given-names></name><name><surname>Madjid</surname><given-names>M.</given-names></name><name><surname>Musher</surname><given-names>D.M.</given-names></name></person-group><article-title>Role of acute infection in triggering acute coronary syndromes</article-title><source>Lancet Infect Dis</source><volume>10</volume><issue>2</issue><year>2010</year><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(09)70331-7</pub-id><pub-id pub-id-type="pmid">20113977</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>G.K.</given-names></name><name><surname>Robertson</surname><given-names>A.K.</given-names></name><name><surname>S&#x000f6;derberg-Naucl&#x000e9;r</surname><given-names>C.</given-names></name></person-group><article-title>Inflammation and atherosclerosis</article-title><source>Annu Rev Pathol</source><volume>1</volume><year>2006</year><fpage>297</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1146/annurev.pathol.1.110304.100100</pub-id><pub-id pub-id-type="pmid">18039117</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>J.R.</given-names></name><name><surname>Foster</surname><given-names>T.J.</given-names></name><name><surname>Cox</surname><given-names>D.</given-names></name></person-group><article-title>The interaction of bacterial pathogens with platelets</article-title><source>Nat Rev Microbiol</source><volume>4</volume><year>2006</year><fpage>445</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">16710325</pub-id></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>McNicol</surname><given-names>A.</given-names></name><name><surname>Israels</surname><given-names>S.J.</given-names></name></person-group><article-title>Beyond hemostasis: the role of platelets in inflammation, malignancy and infection</article-title><source>Cardiovasc Hematol Disord Drug Targets</source><volume>8</volume><year>2008</year><fpage>99</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">18537597</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Lassila</surname><given-names>R.</given-names></name><name><surname>Badimon</surname><given-names>J.J.</given-names></name><name><surname>Vallabhajosula</surname><given-names>S.</given-names></name><name><surname>Badimon</surname><given-names>L.</given-names></name></person-group><article-title>Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood: effects of different stenoses on thrombus growth</article-title><source>Arteriosclerosis</source><volume>10</volume><year>1990</year><fpage>306</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">2317165</pub-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Gando</surname><given-names>S.</given-names></name><name><surname>Kameue</surname><given-names>T.</given-names></name><name><surname>Morimoto</surname><given-names>Y.</given-names></name><name><surname>Matsuda</surname><given-names>N.</given-names></name><name><surname>Hayakawa</surname><given-names>M.</given-names></name><name><surname>Kemmotsu</surname><given-names>O.</given-names></name></person-group><article-title>Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis</article-title><source>Crit Care Med</source><volume>30</volume><year>2002</year><fpage>1729</fpage><lpage>1734</lpage><pub-id pub-id-type="pmid">12163784</pub-id></element-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>R.F.</given-names></name><name><surname>Farag</surname><given-names>A.</given-names></name><name><surname>Mammen</surname><given-names>E.F.</given-names></name><name><surname>Fujii</surname><given-names>Y.</given-names></name></person-group><article-title>Sepsis and antithrombin III, prekallikrein, and fibronectin levels in surgical patients</article-title><source>Am Surg</source><volume>55</volume><year>1989</year><fpage>450</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">2742228</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name><surname>Mesters</surname><given-names>R.M.</given-names></name><name><surname>Mannucci</surname><given-names>P.M.</given-names></name><name><surname>Coppola</surname><given-names>R.</given-names></name><name><surname>Keller</surname><given-names>T.</given-names></name><name><surname>Ostermann</surname><given-names>H.</given-names></name><name><surname>Kienast</surname><given-names>J.</given-names></name></person-group><article-title>Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients</article-title><source>Blood</source><volume>88</volume><year>1996</year><fpage>881</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">8704245</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Shorr</surname><given-names>A.F.</given-names></name><name><surname>Bernard</surname><given-names>G.R.</given-names></name><name><surname>Dhainaut</surname><given-names>J.F.</given-names></name></person-group><article-title>Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome</article-title><source>Crit Care</source><volume>10</volume><year>2006</year><fpage>R92</fpage><pub-id pub-id-type="pmid">16780598</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Green</surname><given-names>J.</given-names></name><name><surname>Doughty</surname><given-names>L.</given-names></name><name><surname>Kaplan</surname><given-names>S.S.</given-names></name><name><surname>Sasser</surname><given-names>H.</given-names></name><name><surname>Carcillo</surname><given-names>J.A.</given-names></name></person-group><article-title>The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure</article-title><source>Thromb Haemost</source><volume>87</volume><year>2002</year><fpage>218</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">11858480</pub-id></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>Madjid</surname><given-names>M.</given-names></name><name><surname>Naghavi</surname><given-names>M.</given-names></name><name><surname>Litovsky</surname><given-names>S.</given-names></name><name><surname>Casscells</surname><given-names>S.W.</given-names></name></person-group><article-title>Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies</article-title><source>Circulation</source><volume>108</volume><year>2003</year><fpage>2730</fpage><lpage>2736</lpage><pub-id pub-id-type="pmid">14610013</pub-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>Naghavi</surname><given-names>M.</given-names></name><name><surname>Barlas</surname><given-names>Z.</given-names></name><name><surname>Siadaty</surname><given-names>S.</given-names></name><name><surname>Naguib</surname><given-names>S.</given-names></name><name><surname>Madjid</surname><given-names>M.</given-names></name><name><surname>Casscells</surname><given-names>W.</given-names></name></person-group><article-title>Association of influenza vaccination and reduced risk of recurrent myocardial infarction</article-title><source>Circulation</source><volume>102</volume><issue>25</issue><year>2000</year><fpage>3039</fpage><lpage>3045</lpage><pub-id pub-id-type="doi">10.1161/01.cir.102.25.3039</pub-id><pub-id pub-id-type="pmid">11120692</pub-id></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P.</given-names></name></person-group><article-title>Inflammation in atherosclerosis</article-title><source>Nature</source><volume>420</volume><year>2002</year><fpage>868</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">12490960</pub-id></element-citation></ref></ref-list><sec id="s0060" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0090">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0005"><caption><title>Supplementary data 1</title></caption><media xlink:href="mmc1.xml"/></supplementary-material>
</p></sec><fn-group><fn id="s0055" fn-type="supplementary-material"><label>Appendix A</label><p id="p0085">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.mehy.2020.110125" id="ir005">https://doi.org/10.1016/j.mehy.2020.110125</ext-link>.</p></fn></fn-group></back></article>